Stocks making the biggest moves premarket: Snowflake, Moderna, Broadcom & more

Snowflake shares surged 24% after Q2 results beat expectations (adjusted EPS $0.62 vs $0.45; revenue $1.55B vs $1.48B) and it raised full-year product revenue guidance, lifting software peers (Datadog +5%, ServiceNow +3%). Offsetting declines included Ultragenyx (-46%) after Phase 3 failed its primary endpoint and Broadcom (-2.5%) on a softer Q4 revenue forecast ($34.8B vs $35.03B). Several other names moved on guidance and earnings beats/misses (Campbell’s ~-7%, Petco +9%, Victoria’s Secret -18%, Netskope +12%, NetApp -8%), keeping the tape mixed but materially driven by earnings/guidance updates.

Analysis

The cleanest signal is not “software is back,” but that the market is paying up for visible near-term reacceleration while punishing any hint of guide conservatism. That favors the higher-quality recurring-revenue stack over legacy infrastructure, but the move is likely crowded after a 20%+ gap; the next leg depends on whether this is true consumption inflection or just a relief squeeze. The read-through is positive for DDOG/NOW, but the bigger loser may be the storage/server complex: modest misses from NTAP/AVGO suggest enterprise budgets are still being allocated selectively, not broadly expanding.

On the consumer side, the tape is reinforcing a bifurcation between trade-down beneficiaries and discretionary weaklings. FIVE’s result supports the idea that lower-income demand is still flowing to value channels, while VSCO and CPB imply pricing power is fragile and promotional intensity remains a margin headwind. If that pattern holds for another 1-2 quarters, the winners are off-price/value retailers; the losers are brands that need full-price sell-through to protect margins.

The binary biotech names are a different regime entirely: RARE is now a capital-allocation story more than an operating story, and MRNA’s downgrade is a reminder that one hot data point can overshoot valuation faster than pipeline risk can be discounted. Near term, the reversals to watch are a softer AI capex commentary from hyperscalers for AVGO/NTAP, or a consumer re-acceleration that would unwind the value-trade premium. Absent those catalysts, the move today likely has 1-3 month follow-through, but only the strongest balance sheets deserve a multiple expansion.

Key Decisions for Investors

• Buy SNOW on the first pullback after the gap if it holds most of the premarket gain for 2-3 sessions; target 4-8 weeks. Risk: a billings/billable-consumption deceleration next quarter would invalidate the reacceleration thesis.
• Pair trade: long FIVE / short VSCO for 1-3 months. Thesis is trade-down share capture versus promotional pressure in discretionary apparel. Cut the pair if FIVE comp trends soften or VSCO shows faster-than-expected margin repair.
• Fade AVGO on strength with a short or put spread after the initial reaction settles. The setup is a multiple-compression trade if AI/networking demand fails to offset even small guide/margin misses. Falsifier: stronger hyperscaler capex commentary or upward margin revision.
• Use NTAP as a tactical short-on-rally, not a chase short today. The deferred-revenue miss matters more than the gross margin beat because it points to slower forward bookings. Reassess if the stock reclaims the pre-earnings level on volume.
• Watch RARE and MRNA, but do not force a trade unless there is a fresh catalyst. Both look like sentiment-driven moves where the next trial/readout or pipeline update, not today’s print, will decide the 3-6 month path.